David Lavie - Hadassah Medical Center

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 25 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

KEYFORM-008: Coformulated Favezelimab and Pembrolizumab (MK4280A) Versus Chemotherapy in Relapsed/refractory Classical Hodgkin Lymphoma

David Lavie,John Timmerman,Ramon Garcia Sanz,Won Seog Kim,Tae Min Kim,Abraham Avigdor,Daan Dierickx,Deepa Jagadeesh,Daniel Molin,Muhit Ozcan,Omur Gokmen Sevindik,Hayder Saeed,Yulia Sidi,Pallavi Pillai,Patricia Marinello,Alex Francisco Herrera

Journal of clinical oncologyno. 16_suppl (2023): TPS7585-TPS7585

引用0浏览0引用

FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB

P. Armand,P. L. Zinzani,J. Timmerman,N. Johnson,D. Lavie, K. Thiagarajan,B. Topp,P. Pillai,A. F. Herrera

Hematological Oncologyno. S2 (2023): 163-165

引用0浏览0引用

P1067: estimating the relative efficacy of favezelimab when used in combination with pembrolizumab in patients with pd-1–refractory classical hodgkin lymphoma

Philippe Armand,Pier Luigi Zinzani,John M. Timmerman, Nathalie A. Johnson,David Lavie,Kannan Thiagarajan,Brian Topp,Pallavi Pillai,Alex F. Herrera

HemaSphereno. S3 (2023): e8856772-e8856772

引用0浏览0引用

BELLWAVE-003: A Phase 2 Dose Escalation, Confirmation, and Cohort Expansion Study of Nemtabrutinib in Hematologic Malignancies

Guilherme Fleury Perini,Carolyn Owen,Muhit Ozcan,Wojciech Jurczak,Eva Gonzalez Barca,Tomasz Wrobel,David Lavie,Arvind Chaudhry,Paolo Ghia, Yan Xu,David Boardman, Jing Yang,Ohad Benjamini

Journal of clinical oncology（2023）

引用0浏览0引用

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Muhıt Özcan,Yuqin Song,Seung‐Tae Lee,Felix Mensah,Dipenkumar Modi,Alexander Fosså,Won Seog Kim,Ewa Paszkiewicz‐Kozik,Yazeed Sawalha,Ömür Gökmen Sevindik,Lalita Norasetthada,Armando Santoro,Kumudu Pathiraja,Samhita Chakraborty,Patricia Marinello,David Lavie

HemaSphere（2023）

引用0浏览0引用

Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy

David Lavie,Muhit Ozcan,Arvind Chaudhry,Xuan Zhou,Ima Paydar,Mohammed Z. H. Farooqui,Paolo Ghia

BLOOD (2023): 3287

引用0浏览0引用

Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5

Irit Avivi Mazza,Won Seog Kim, Shen Ko,Carlos Grande,David Lavie,David Chism, Mostafa Seliem,Edwin E. Jeng,Neha Joshi,Satya Siddani,Wissam Assaily,Mariana Sacchi,Minh Dinh,Abraham Avigdor

Blood (2023): 438

引用0浏览0引用

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie,John Timmerman,Ramon Garcia-Sanz,Won Seog Kim,Tae Min Kim,Abraham Avigdor,Daan Dierickx,Deepa Jagadeesh,Daniel L. Molin,Muhit Ozcan,Omur Gokmen Sevindik,Hayder Saeed,Yulia Sidi,Pallavi Pillai,Patricia Marinello,Alex F. Herrera

Blood（2023）

引用0浏览0引用

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Nathalie A. Johnson,David Lavie,Peter Borchmann,Gareth P. Gregory,Alex F. Herrera,Leonard Minuk,Vladan Vučinić,Philippe Armand,Abraham Avigdor,Robin Gasiorowski,Yair Herishanu,Colm Keane,John Kuruvilla,Rachel West,Pallavi Pillai,Patricia Marinello,John M. Timmerman

HemaSphereno. S3 (2023): e0274602-e0274602

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn